<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845831</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00063642</org_study_id>
    <nct_id>NCT01845831</nct_id>
  </id_info>
  <brief_title>Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes</brief_title>
  <official_title>Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with
      increased risk of medical complications and death. Improved glucose control with insulin
      injections may improve clinical outcome and prevent some of the hospital complications.
      Glargine (Lantus®) insulin injection is the most common treatment of diabetes in the
      hospital. Sitagliptin (Januvia®)is effective in lowering blood glucose. In a recent pilot
      study aiming to determine differences in glycemic control between treatment with sitagliptin
      (Januvia®) alone or in combination with basal insulin and basal bolus regimen in general
      medicine and surgery patients with type 2 diabetes (T2D). The investigators found that
      treatment with sitagliptin alone or in combination with basal insulin resulted in similar
      glycemic control compared to basal bolus regimen.

      The investigators will conduct a prospective RCT aimed to determine the safety and efficacy
      of sitagliptin therapy for in-hospital and post-discharge management of general medicine and
      surgical patients with T2D. A total of 280 patients with known history of diabetes will be
      randomized to receive sitagliptin plus basal (glargine) insulin once daily (group 1), or
      basal bolus regimen with glargine once daily and aspart or lispro insulin before meals (group
      2). If needed, patients in the treatment groups will receive correction doses of rapid-acting
      insulin in the presence of hyperglycemia (BG &gt; 140 mg/dl). The overall hypothesis is that
      treatment with sitagliptin in combination with basal insulin in patients with type 2 diabetes
      will result in a similar improvement in hospital and post-discharge glycemic control and in a
      lower frequency of hypoglycemic events than treatment with basal bolus insulin regimen with
      glargine once daily and lispro insulin before meals.

      Patients will be recruited at Grady Memorial Hospital, Emory University Hospital, University
      of Michigan, Ohio State University and Temple University
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To determine whether in-hospital glycemic control, as measured by mean daily
      blood glucose concentration and frequency of hypoglycemic events, is different between
      treatment with sitagliptin (Januvia®) in combination with basal insulin (glargine) and basal
      bolus regimen (glargine and rapid-acting insulin analog) in general medicine and surgery
      patients with T2D. Patients with T2D treated with diet and/or OAD or with low total daily
      dose insulin therapy (≤0.6 unit/kg/day) will be randomized to receive sitagliptin plus
      glargine insulin (group 1) or basal bolus regimen with glargine once daily and rapid-acting
      insulin (lispro or aspart) before meals (group 2). If needed, patients in the 2 treatment
      groups will receive supplemental (correction) doses of rapid-acting insulin before meals for
      BG &gt; 140 mg/dl.

      Specific Aim 2: To determine the efficacy and safety of an A1C based discharge algorithm in
      controlling BG after discharge in patients with T2D. Patients who participate in the
      in-hospital (Aim 1) arm will be invited to enroll in this open label prospective outpatient
      study. The total duration of the study is 6 months. Patients with HbA1c ≤ 7% will be
      discharged on the combination of metformin and sitagliptin (Janumet ®) twice daily. Those
      with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ®)
      twice daily plus glargine insulin at 50% of the inpatient glargine dose. Those with HbA1c &gt;
      9% will be discharged on metformin and sitagliptin (Janumet ®) twice-daily plus glargine
      insulin at 80% of the inpatient dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Blood Glucose Concentration After First Day of Treatment</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>The average blood glucose (BG) concentration after the first day of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage of Blood Glucose Readings Between 3.9 - 7.8 mmol/L</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage of Blood Glucose Readings Between 3.9 - 10.0 mmol/L</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage of Blood Glucose Readings Between 5.6 - 7.8 mmol/L</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage of Blood Glucose Readings Greater Than 13.3 mmol/L</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>Post Hospital Discharge Month 3, Month 6</time_frame>
    <description>The mean HbA1C measured at 3 months and 6 months post hospitalization. HbA1C is an indicator of diabetes control; below 6.0% is normal, 6.0% to 6.4% indicates prediabetes, and 6.5% or over indicates diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Hypoglycemic Event</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>The number of participants who had a hypoglycemic event during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin Dose</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Daily insulin requirement (units per day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Length of hospital stay in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure Rate</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment &gt; 0.5 mg/dL from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality Rate</measure>
    <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
    <description>Mortality is defined as death occurring during admission.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin + glargine (Hospital)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal bolus (Hospital)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and sitagliptin + glargine 50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and sitagliptin + glargine 80%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HbA1c &gt; 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.</description>
    <arm_group_label>Sitagliptin + glargine (Hospital)</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Bolus</intervention_name>
    <description>Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
    <arm_group_label>Basal bolus (Hospital)</arm_group_label>
    <other_name>Glargine (Lantus) + aspart (Novolog) or lispro (Humalog)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Sitagliptin</intervention_name>
    <description>Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.</description>
    <arm_group_label>Metformin and Sitagliptin</arm_group_label>
    <arm_group_label>Metformin and sitagliptin + glargine 50%</arm_group_label>
    <arm_group_label>Metformin and sitagliptin + glargine 80%</arm_group_label>
    <other_name>Janumet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.
Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day.</description>
    <arm_group_label>Sitagliptin + glargine (Hospital)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine 50%</intervention_name>
    <description>Glargine will be prescribed at 50% of daily hospital dose.</description>
    <arm_group_label>Metformin and sitagliptin + glargine 50%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine 80%</intervention_name>
    <description>Glargine will be prescribed at 80% of daily hospital dose.</description>
    <arm_group_label>Metformin and sitagliptin + glargine 80%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years admitted to medicine and surgery
             services.

          2. A known history of Type 2 Diabetes &gt; 1 month, receiving either diet alone, oral
             antidiabetic agents: sulfonylureas and metformin as monotherapy or in combination
             therapy (excluding DPP-4 inhibitors) or low-dose (≤ 0.6 units/kg/day) insulin therapy.

          3. Subjects with a blood glucose &gt;140 mg and &lt; 400 mg/dL at time of randomization without
             laboratory evidence of diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive
             serum or urinary ketones).

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with increased BG concentration, but without a history of diabetes (stress
             hyperglycemia).

          3. Subjects with a history of type 1 diabetes (suggested by BMI &lt; 25 requiring insulin
             therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic
             state, or ketonuria) [46].

          4. Treatment with DPP4 inhibitor or Glucagon like peptide 1 (GLP1) analogs during the
             past 3 months prior to admission.

          5. Acute critical illness or coronary artery bypass graft (CABG) surgery expected to
             require admission to a critical care unit.

          6. Subjects with gastrointestinal obstruction or adynamic ileus or those expected to
             require gastrointestinal suction.

          7. Medical or surgical patients expected to be kept NPO for &gt;24-48 hours after admission
             or after completion of surgical procedure.

          8. Patients with clinically relevant pancreatic or gallbladder disease.

          9. Patients with acute myocardial infarction, clinically significant hepatic disease or
             significantly impaired renal function (GFR &lt; 30 ml/min).

         10. Treatment with oral or injectable corticosteroid = or &gt; prednisone 5 mg/per day.

         11. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         12. Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>March 8, 2017</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>DPP4 inhibitors</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Glargine</keyword>
  <keyword>RCT</keyword>
  <keyword>basal insulin</keyword>
  <keyword>hospital hyperglycemia</keyword>
  <keyword>inpatient diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between August 23, 2013 and July 27, 2015.</recruitment_details>
      <pre_assignment_details>Of the 292 subjects who consented for participation, 279 began the inpatient study phase. Two hundred and fifty-three participants began the outpatient study phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin + Glargine (Hospital)</title>
          <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="P2">
          <title>Basal Bolus (Hospital)</title>
          <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="P3">
          <title>Metformin and Sitagliptin</title>
          <description>Outpatient Phase:
Patients with HbA1c ≤ 7% during the inpatient phase were discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
Metformin and sitagliptin: Patients with HbA1c ≤ 7% were discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months</description>
        </group>
        <group group_id="P4">
          <title>Metformin and Sitagliptin + Glargine 50%</title>
          <description>Outpatient Phase:
Patients with HbA1c between 7% and 9% during the inpatient phase were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
Metformin and sitagliptin + glargine 50%: Patients with HbA1c between 7% and 9% were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months</description>
        </group>
        <group group_id="P5">
          <title>Metformin and Sitagliptin + Glargine 80%</title>
          <description>Outpatient Phase:
Patients with HbA1c &gt; 9% during the inpatient phase were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
Metformin and sitagliptin + glargine 80%: Patients with HbA1c &gt; 9% were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Inpatient Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Outpatient Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin + Glargine (Hospital)</title>
          <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="B2">
          <title>Basal Bolus (Hospital)</title>
          <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="277"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="138"/>
                    <count group_id="B2" value="139"/>
                    <count group_id="B3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="11.4"/>
                    <measurement group_id="B2" value="57.1" spread="10.4"/>
                    <measurement group_id="B3" value="56.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="138"/>
                    <count group_id="B2" value="139"/>
                    <count group_id="B3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Race/Ethnicity data were missing for three participants in the Basal/bolus group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="138"/>
                    <count group_id="B2" value="136"/>
                    <count group_id="B3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="138"/>
                    <count group_id="B2" value="136"/>
                    <count group_id="B3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="138"/>
                    <count group_id="B2" value="136"/>
                    <count group_id="B3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Glucose Concentration After First Day of Treatment</title>
        <description>The average blood glucose (BG) concentration after the first day of treatment</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Concentration After First Day of Treatment</title>
          <description>The average blood glucose (BG) concentration after the first day of treatment</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.7"/>
                    <measurement group_id="O2" value="9.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Blood Glucose Readings Between 3.9 - 7.8 mmol/L</title>
        <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Blood Glucose Readings Between 3.9 - 7.8 mmol/L</title>
          <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
          <units>percentage of blood glucose readings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="28.0"/>
                    <measurement group_id="O2" value="29.7" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Blood Glucose Readings Between 3.9 - 10.0 mmol/L</title>
        <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Blood Glucose Readings Between 3.9 - 10.0 mmol/L</title>
          <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
          <units>percentage of blood glucose readings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="31.5"/>
                    <measurement group_id="O2" value="59.6" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Blood Glucose Readings Between 5.6 - 7.8 mmol/L</title>
        <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Blood Glucose Readings Between 5.6 - 7.8 mmol/L</title>
          <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
          <units>percentage of blood glucose readings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="21.8"/>
                    <measurement group_id="O2" value="23.5" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Blood Glucose Readings Greater Than 13.3 mmol/L</title>
        <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Blood Glucose Readings Greater Than 13.3 mmol/L</title>
          <description>Differences in glycemic control as measured by mean daily blood glucose (BG) concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2D.</description>
          <units>percentage of blood glucose readings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="22.1"/>
                    <measurement group_id="O2" value="16.7" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1C</title>
        <description>The mean HbA1C measured at 3 months and 6 months post hospitalization. HbA1C is an indicator of diabetes control; below 6.0% is normal, 6.0% to 6.4% indicates prediabetes, and 6.5% or over indicates diabetes.</description>
        <time_frame>Post Hospital Discharge Month 3, Month 6</time_frame>
        <population>253 subjects who participated in the inpatient phase and were invited to complete the outpatient phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin and Sitagliptin</title>
            <description>Outpatient Phase:
Patients with HbA1c &lt; 7% during the inpatient phase were discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
Metformin and sitagliptin: Patients with HbA1c ≤ 7% were discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin and Sitagliptin + Glargine 50%</title>
            <description>Outpatient Phase:
Patients with HbA1c between 7% and 9% during the inpatient phase were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
Metformin and sitagliptin + glargine 50%: Patients with HbA1c between 7% and 9% were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin and Sitagliptin + Glargine 80%</title>
            <description>Outpatient Phase:
Patients with HbA1c &gt; 9% during the inpatient phase were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
Metformin and sitagliptin + glargine 80%: Patients with HbA1c &gt; 9% were discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1C</title>
          <description>The mean HbA1C measured at 3 months and 6 months post hospitalization. HbA1C is an indicator of diabetes control; below 6.0% is normal, 6.0% to 6.4% indicates prediabetes, and 6.5% or over indicates diabetes.</description>
          <population>253 subjects who participated in the inpatient phase and were invited to complete the outpatient phase.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread=".5"/>
                    <measurement group_id="O2" value="8.0" spread="0.6"/>
                    <measurement group_id="O3" value="11.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread=".8"/>
                    <measurement group_id="O2" value="7.3" spread="1.1"/>
                    <measurement group_id="O3" value="8.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.0"/>
                    <measurement group_id="O2" value="7.3" spread="1.3"/>
                    <measurement group_id="O3" value="8.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Hypoglycemic Event</title>
        <description>The number of participants who had a hypoglycemic event during hospitalization.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Hypoglycemic Event</title>
          <description>The number of participants who had a hypoglycemic event during hospitalization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Glucose &lt;3.9 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Glucose &lt;2.2 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin Dose</title>
        <description>Daily insulin requirement (units per day).</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Insulin Dose</title>
          <description>Daily insulin requirement (units per day).</description>
          <units>units per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="16.2"/>
                    <measurement group_id="O2" value="34.0" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Length of hospital stay in days.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Length of hospital stay in days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure Rate</title>
        <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment &gt; 0.5 mg/dL from baseline).</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Renal Failure Rate</title>
          <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment &gt; 0.5 mg/dL from baseline).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality Rate</title>
        <description>Mortality is defined as death occurring during admission.</description>
        <time_frame>Duration of Hospitalization (Up to 10 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Glargine (Hospital)</title>
            <description>Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus (Hospital)</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality Rate</title>
          <description>Mortality is defined as death occurring during admission.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (2 years) including the inpatient and outpatient phases.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin + Glargine (Hospital)</title>
          <description>Inpatient Phase:
Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
Sitagliptin + glargine: Sitagliptin and Glargine once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="E2">
          <title>Basal Bolus (Hospital)</title>
          <description>Inpatient Phase:
Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + correction doses of rapid acting insulin if needed</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment &gt; 0.5 mg/dL from baseline).</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reoperation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As a single DPP-4 inhibitor, sitagliptin, was used, results cannot be generalized to other incretin-based drugs. Additionally, the proportion of surgical patients was small, and the results may not be generalized to all surgical patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

